NEPTUNE

Information for Professionals

Nephrotic Syndrome Study Network

The Nephrotic Syndrome Study Network (NEPTUNE) includes patients presenting with significant proteinuria with a clinical indication for a kidney biopsy. The study participants will be classified according to the kidney biopsy results into one of three subcohorts, including Minimal change disease/Focal segmental glomerulosclerosis; Membranous nephropathy; and other conditions.

PI: Matthias Kretzler, M.D.

Study Aims

Specific Aim 1: To determine the rates and predictors of clinical remission of FSGS/MCD.

Specific Aim 2: To identify gene expression profiles from renal biopsies of participants with FSGS/MCD that can be used to classify participants into distinct molecular subgroups.

Specific Aim 3: To identify the transcriptional networks that are associated with individual genetic causes of FSGS/MCD; namely, mutations in NPHS1, NPHS2, LAMB2, PLCE1/NPHS3 and WT1.

Specific Aim 4: To determine the rates and predictors of clinical remission of MN.

Specific Aim 5: To identify gene expression profiles from renal biopsies of participants with MN that can be used to classify participants into distinct molecular subgroups.

Specific Aim 6: To determine the effect of adjuvant (non-immunomodulating) therapy on the clinical remission of Nephrotic Syndrome.

Specific Aim 7: To determine the rates of major medical complications in patients treated for Nephrotic Syndrome.

Specific Aim 8: To evaluate the quality of life and its trends in participants undergoing treatment for Nephrotic Syndrome.

Nephrotic Syndrome Study Network Visit Schedule

Click to view full schedule in a new window

View Schedule